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Abstract 
Synthetic opioids are a drug class of particular concern due to their incredibly high potency and the 
large public health threat that they pose. These compounds have also seen significant modification, 
highlighting the importance of developing techniques that can detect them without relying on 
databases or certified reference materials. This work provides a comprehensive investigation into the 
detection and profiling of synthetic opioids from the perspective of both drug screening in biological 
matrices and analysis of seized drug samples. 
Collision-induced dissociation studies were conducted on a range of different synthetic opioid 
standards and common product ions belonging to each opioid subclass were identified for use in  
non-targeted screening strategies. Product ion searching, Kendrick Mass Defect analysis and 
recursive feature extraction approaches were evaluated for data analysis. Product ion searching and 
Kendrick mass defect analysis proved effective, with estimated screening cut-offs proposed of  
0.05 ng/mL and 0.1 ng/mL, respectively. Recursive feature extraction was found to have a high 
sensitivity for the detection of spiked compounds, however unbiased extraction of all compounds 
within a sample presented issues with relevance for screening. 
Machine learning approaches were investigated for the identification of unknown compounds. A 
Naïve Bayes classification model was trained, exploiting the common fragmentation pathways 
identified, to predict the opioid subclass of a sample with 89.5% accuracy. Additionally, a Gaussian 
Process Regression model was optimised to predict the experimental relative retention time of a 
compound based on its molecular features. Relative retention times were predicted for 79.7% of the 
samples within ±0.1 of their experimental value. By using these models as complementary 
approaches putative identities of unknown compounds can be proposed with greater confidence 
before confirmation using certified reference materials. 
A preliminary study was also conducted into the synthetic route profiling of acetyl fentanyl. Several 
common impurities were identified, as well as a number of impurities that were unique to a specific 
method. These impurities can provide an analyst with an indication of the method used in the 
synthesis of a seized sample. Furthermore, a statistical approach was taken, with the creation of 
principal component analysis plots and classification models. The PCA plots showed distinct 
separation between samples made with different methods and the trained classification models 
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displayed high accuracy. These results should be reviewed in context, however, as small sample sizes 
were used in this preliminary study. 
 

